Here, microbiology experts Tim Sandle, Tony Cundell and AstraZeneca’s Miriam Guest reflect on key developments in pharmaceutical microbiology during 2022.
This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts:
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited
Dr Tony Cundell, PhD, Principal Consultant, Microbiological Consulting, LLC
Miriam Guest, Principal Microbiologist at AstraZeneca.
Regulation, particularly Annex 1, was identified as a key focus for 2022.
“Clearly the number one challenge in 2022, as mandated by the EU GMP Guidelines for the Manufacture of Sterile Medicinal Products Annex 11, is the development of a Contamination Control Strategy (CCS),” Tony Cundell noted. He warned, “Implementation of a CCS will require more than writing documents.”
Changes may be needed, such as improved corporate culture, information management, retraining of personnel, and upgraded facilities, suggested Cundell. He questioned how regulators will enforce revisions to Good Manufacturing Practice (GMP) regulations.
Another major topic covered by the experts was technological advances.
According to Tim Sandle, new technologies mean: “The skill profile of the ‘traditional microbiologist’ is altering…”, affecting microbiologists working in the modern pharmaceutical microbiology lab.
Specific technologies expected to be pivotal include microbial identification matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF).
“Connectivity between the laboratory and manufacturing facility is growing, and the use of digital tools will continue to build that integration,” commented Miriam Guest. She emphasised that for technological connectivity to be established, interpersonal connectivity with IT colleagues is important for smooth integration.
What were the main challenges for pharmaceutical microbiology in 2022?
Tim Sandle: The adoption of EU GMP Annex 1 is occupying a lot of time across the pharmaceutical sector and various projects will stem from that in relation to contamination control. There is an expectation that more thorough, science-based quality risk assessments are developed and that these are ‘proactive’, in terms of looking for contamination risks before they occur.
Ideally, microbiology needs to transition to adopt as much real-time assessment as possible, such as online water monitoring and assessing cleanrooms through technologies like spectrophotometric-based viable and inert particle counting.
Within the microbiology laboratory, some challenges remain with data integrity, especially with the reading of agar plates. Automated colony counters have advanced but there remain some limitations when it comes to mixed cultures, merged colonies, colonies close to edge of plates and so on. This places a continued reliance upon plate reading and the limitations of human vision. This also occupies a large resource, given the US Food and Drug Administration (FDA) requirement for double plate checking using a second ‘independent’ person.
Tony Cundell: Perhaps the second greatest challenge is the ongoing transition from products based on small molecules to large molecules to cellular therapies. Cellular products directed towards personalised medicine have short manufacturing cycles, small batch sizes, demanding analytical methods, and short shelf lives. Their manufacturing processes are viewed as going from vein to vein involving cell donation, cell selection, gene modification, cell expansion, finishing, distribution, to administration. All require aseptic manipulation, hence have microbial contamination risks. The US federal drug GMP regulations that first became official in 1977 and their European counterparts will need to be re-interpreted for this new generation of products. The FDA is doing this through the publications of Guidance for Industry.
It has been important to build and maintain relationships with our colleagues in IT, to ensure that new technology adoptions are integrated and meet the requirements to operate in a GMP laboratory.”
Miriam Guest: We are creating more ‘data’, with the adoption of modern techniques. Our data isn’t necessarily an agar plate anymore, with digital records, or direct capture of results – this is fairly new in our microbiology labs that are steeped in tradition. It has been important to build and maintain relationships with our colleagues in IT, to ensure that new technology adoptions are integrated and meet the requirements to operate in a GMP laboratory.
What is the most important lesson you learned in 2022 relating to pharmaceutical microbiology and manufacturing?
Innovation will be driven by an adequate supply of scientifically trained graduates from our universities and technical institutions with the appropriate on-the-job training.”
Tony Cundell: Contract manufacturing organisations (CROs), start-up companies, established pharmaceutical companies and regulatory agencies are having difficulty recruiting and retaining technically-trained personnel. Innovation will be driven by an adequate supply of scientifically trained graduates from our universities and technical institutions with the appropriate on-the-job training.
Tim Sandle: The skill profile of the ‘traditional microbiologist’ is altering and an understanding of biochemistry and molecular biology is often useful to meet the evolving challenges of the modern laboratory.
How did technological advances in 2022 benefit the pharmaceutical microbiology sector?
Tim Sandle: Although it is not new, matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) for microbial identification has become the required piece of equipment for processing a large number of samples. This is particularly important in sterile manufacturing facilities where the requirement is for any colony from a Grade B cleanroom to be identified, in addition to Grade A isolates, together with a representative selection from other cleanrooms. Large scale identification also plays an important part in designing the cleaning and disinfection aspects of the contamination control strategy. MALDI-TOF works on the basis of the ionisation of chemical compounds and measurements of their mass to charge (m/z) ratio. These create a specific microbial fingerprint (a peptide mass fingerprint) allowing identification upon comparison with databases. The time to result is around one minute.
Miriam Guest: Not only are we using amplified adenosine triphosphate (ATP) bioluminescence for rapid sterility on our new and legacy products, we are also applying it in suspect positive media fill or sterility test units where we have a product that renders the media turbid and we need an unequivocal result.
We had one instance, on technical material, where we needed to meet tight timelines. While it was not made under true aseptic conditions, nor manufactured for human use, we were confident it would meet the sterility requirement we needed for the subsequent testing.
[Using ATP bioluminescence for rapid sterility] really highlighted the benefits of adopting new technology in the microbiology lab”
We took the step to execute a sterility test via the ATP bioluminescence (we did a quick sample screen prior to ensure it did not interfere) and despite the broth looking absolutely crystal clear, we got a positive hit on the ATP. We executed our standard subculture steps, and did a broth extract, where we executed a MALDI-TOF prior to the observation of visible growth on the subculture agar plates. This early information on the ID enabled us to ensure our subculture step was suitable to recover the likely organism. In this circumstance, it really highlighted the benefits of adopting new technology in the microbiology lab and supported project timelines. We simply would not have been able to achieve this if we only had traditional techniques available.
Tim Sandle: Microbiologists are deploying digital tools to help with the preparation and review of contamination control. Where these are based on the risk tool hazard analysis and critical control points (HACCP) they can prove to be especially useful when looking for sources of contamination, vectors, opportunities for risk reduction and monitoring locations.
The safety and efficacy of mRNA vaccines should be a game changer and is the likely solution to antibiotic-resistant microorganisms and emerging viral pathogens.”
Tony Cundell: The safety and efficacy of mRNA vaccines should be a game changer and is the likely solution to antibiotic-resistant microorganisms and emerging viral pathogens. Our industry, assisted by past public research funding and the flexibility and responsiveness of regulatory agencies such as the FDA, was able to progress from the viral base sequencing to FDA emergency authorisation of a SARS CoV-2 vaccine in 11 months was truly remarkable. The previous record for vaccine development and approval was four years for the measles vaccine. Perhaps we will see a universal flu vaccine in the near future.
What were the most exciting innovations in pharmaceutical microbiology in 2022?
Tim Sandle: The use of microorganisms to create medicines and an understanding of how microorganisms interact with medicines, especially in relation to the human gut microbiome continues to be an exciting area, especially in the field of personalised medicines.
Another exciting development is the promise that modifying the composition of our microbiome will protect us from bacterial infection and even mitigate chronic diseases.”
Tony Cundell: Another exciting development is the promise that modifying the composition of our microbiome will protect us from bacterial infection and even mitigate chronic diseases. For example, in September 2022, the company Rebiotix, Inc. presented their pathway for regulatory approval to the FDA Vaccines and Related Biological Products Advisory Committee for a faecal microbiota-based live biotherapeutic to treat recurrent Clostridioides difficile infection, which is a major Healthcare Acquired Infection (HAI). The next step beyond faecal matter transplantation will be treatment with selected intestinal bacterial cultures.
Tim Sandle: One interesting area is with Raman spectroscopy, which has been demonstrated to be capable of assessing samples to allow single-cell analyses and identification of microbes from various types of samples.
Technologies that I find exciting are biofluorescent particle counting methods (BFPC) for pharmaceutical-grade water monitoring and air cleanliness monitoring in aseptic processing areas and use of biomarkers for sterility testing (Huang et al, 2022 The ratio of nicotinic acid to nicotinamide as a microbial biomarker for assessing cell therapy product sterility Molecular Therapy Methods & Clinical Development 25: 410-4252). BFPC will move environmental monitoring to a real-time in-process control while biomarker measurement is a unique approach to sterility testing.
Miriam Guest: Connectivity between the laboratory and manufacturing facility is growing, and the use of digital tools will continue to build that integration. I think we’ll see our labs change significantly over the next five to 10 years.
Annex 1 highlights the topic of automation in the manufacturing area as a way to eliminate human interventions and the same can be applied to the quality control (QC) testing environment.”
Automation is another area, where we have implemented automated solutions and will continue to look for opportunities as they become accessible to the microbiology labs. Annex 1 highlights the topic of automation in the manufacturing area as a way to eliminate human interventions and the same can be applied to the quality control (QC) testing environment. This has a range of benefits, from the efficiency in enabling us to focus our skilled microbiologists on areas where they can add the most value, but also in having tracible audit trails of activities associated with a sample.
What major regulations will impact the pharmaceutical microbiology sector in the next five years?
Tim Sandle: Currently, EU GMP Annex 1 is the main challenge that many pharmaceutical microbiologists are examining. While most facilities will be meeting most of the requirements, it’s the level of detail that presents a challenge. Especially with collating evidence, formulating risk assessments and adding detail to the contamination control strategy.
It is expected that the FDA will update their aseptic processing guidance, using Annex 1 as a model, given that the FDA were one of the organisations who were part of the Annex 1 development process via Pharmaceutical Inspection Co-operation Scheme (PIC/S).
In the recent FDA guidance on nanomedicine, the microbiological control aspects are featured. Nanotechnology and the innovations with advanced cellular products will create challenges in terms of process controls and with the qualification of test methods.
We also have some strong chapters in the European and US Pharmacopeias for rapid and alternative microbiological methods, but the regulatory part is lagging. It is possible that more guidance will emerge to fill this space.
Tony Cundell: Microbiologists everywhere welcome the emphasis placed in the EU GMP Annex 1 revision on Quality Risk Management (QRM). We will have more opportunities to influence the development of future formulations and manufacturing processes.
The emphasis on data integrity and failure investigations during regulatory inspections will undoubtedly impact pharmaceutical microbiology.”
The emphasis on data integrity and failure investigations during regulatory inspections will undoubtedly impact pharmaceutical microbiology. The subjectivity and variability of plate counting has spiked an interest in the qualification and implementation of automated plate readers.
Miriam Guest: We will see more guidance provided on the application of machine learning and artificial intelligence. I think it will be important that we work with our regulators to ensure activities are executed within the framework of clear guidance.
I think it will be important that we work with our regulators to ensure activities are executed within the framework of clear guidance.”
As new technologies become business as usual, I expect the regulators will provide clearer stand-alone chapters for some of the methods that are currently classified under the ‘alternative microbiology methods’. As these move into the mainstream, there will be new technologies following, and the appropriate frameworks will be provided.
The other side is the pipeline of new pharmaceutical products. As we transform how we make our medicines, we will transform our control strategies, and the regulatory guidance today will transform alongside.
About the authors
DrTim Sandle has over 25 years’ experience of microbiological research and biopharmaceutical processing. Tim is a member of several editorial boards and has authored 30 books on microbiology, healthcare and pharmaceutical sciences. Tim is Head of Microbiology for Bio Products Laboratory Limited (BPL) in the UK and is a visiting tutor at both the University of Manchester and UCL.
Miriam Guest is a Principal Microbiologist at AstraZeneca, working in the New Modalities and Parenteral Development group; based at their Macclesfield site in the UK. Miriam has worked in pharmaceutical development for over 20 years, in both microbiology and formulation laboratories and GMP manufacturing environments; more recently supporting complex supply chains and designing robust control strategies, including the associated regulatory authoring and interactions. She leads the AZ Global Microbiology Forum, bringing together the global network of microbiology labs to drive standardisation and quality principles in microbiology.
Dr Tony Cundell has a PhD in Microbiology from the Lincoln University, New Zealand. He consults in the areas of microbial risk assessment, regulatory affairs and microbiological testing. Prior to November 2013 he worked for Merck Research Laboratories in Summit, New Jersey as the Senior Principal Scientist in early phase drug development. Earlier in his career, Tony worked at a director level in Quality Control and Product Development organisations at the New York Blood Center, Lederle Laboratories, Wyeth Pharmaceuticals and Schering-Plough. He is a member of the 2015‑2020 USP Microbiology Committee of Experts where he takes a leadership role in the area of modern microbiology methods.
Huang et al. The ratio of nicotinic acid to nicotinamide as a microbial biomarker for assessing cell therapy product sterility. Molecular Therapy – Methods & Clinical Development. 2022Jun;25:410–24. Available at: https://pubmed.ncbi.nlm.nih.gov/35573051/
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
Very good overview of the key events shaping the microbial world, especially with what rapid microbiology can deliver for pharmaceutical microbiology.